Drug Profile
CPC 250
Alternative Names: CPC-250Latest Information Update: 07 Oct 2021
Price :
$50
*
At a glance
- Originator Chase Pharmaceuticals
- Class Antidementias
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease